Strong convergence theorem for split monotone variational inclusion with constraints of variational inequalities and fixed point problems.

In this paper, inspired by Jitsupa et al. (J. Comput. Appl. Math. 318:293-306, 2017), we propose a general iterative scheme for finding a solution of a split monotone variational inclusion with the constraints of a variational inequality and a fixed point problem of a finite family of strict pseudo-contractions in real Hilbert spaces. Under very mild conditions, we prove a strong convergence theorem for this iterative scheme. Our result improves and extends the corresponding ones announced by some others in the earlier and recent literature.

General iterative methods for systems of variational inequalities with the constraints of generalized mixed equilibria and fixed point problem of pseudocontractions.

In this paper, we introduce two general iterative methods (one implicit method and one explicit method) for finding a solution of a general system of variational inequalities (GSVI) with the constraints of finitely many generalized mixed equilibrium problems and a fixed point problem of a continuous pseudocontractive mapping in a Hilbert space. Then we establish strong convergence of the proposed implicit and explicit iterative methods to a solution of the GSVI with the above constraints, which is the unique solution of a certain variational inequality. The results presented in this paper improve, extend, and develop the corresponding results in the earlier and recent literature.

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

OBJECTIVES: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a standard first-line treatment for EGFR-mutant patients with non-small cell lung cancer (NSCLC). However, it remains unclear whether frontline EGFR TKIs affect subsequent chemo-sensitivity in EGFR-mutant patients. This study compared chemo-sensitivity in patients treated with post-TKI chemotherapy and first-line chemotherapy controls. MATERIALS AND METHODS: This study included 203 EGFR-mutant patients. The study group contained 68 patients treated with chemotherapy after first-line EGFR-TKI and the control group contained 135 patients who received first-line chemotherapy. The response rate (RR), progression-free survival (PFS) and overall survival (OS) were assessed. RESULTS: In study group, the RR of chemotherapy was 13.2% compared with 34.1% in the control group (P=0.002). The median PFS of chemotherapy in the control group was significantly longer than in the study group (6.9 vs. 3.9 months, P<0.001), while the RR (76.5% vs. 68.9%, P=0.259) and PFS (11.0 vs. 10.2 months) of EGFR-TKI were similar between first- and second-line treatment. Cox regression analyses indicated that prior EGFR-TKI treatment had a higher risk for disease progression during chemotherapy treatment [hazard ratio (HR)=3.06; 95% CI=2.12-4.42, P<0.001]. Median overall survival was 31.7 months in the control group and 23.5 months in the study group (P<0.001). The adjusted HR for death in the study group was 1.91 (95% CI=1.33-2.76; P<0.001). CONCLUSION: In EGFR-mutant patients, frontline EGFR-TKI significantly reduced the sensitivity of subsequent chemotherapy compared with that of TKI-naïve frontline chemotherapy. These findings need to be validated in further randomized trials.